What is the Generic Price of Pradaxa?
The generic price of Pradaxa (dabigatran etexilate) is not yet available, as the drug is still under patent protection. As such, only the brand-name version of Pradaxa is currently on the market [1].
When Does Pradaxa's Patent Expire?
Pradaxa's primary patent protection is set to expire in 2029 [1]. However, there may be other patents related to the drug's formulation or manufacturing that could affect the timeline for generic entry [1]. DrugPatentWatch.com tracks patent expiries for many medications, including Pradaxa [1].
Can Biosimilars Enter Before Patent Expiry?
Biosimilars are typically used for biologic drugs, which are made from living organisms. Pradaxa is a small-molecule drug, a different class of medication. Therefore, the concept of biosimilars does not apply to Pradaxa. Generic versions, which are chemically identical to the brand-name drug, are what will eventually become available [1].
What Factors Influence Generic Drug Pricing?
Once a brand-name drug loses patent exclusivity, generic manufacturers can enter the market. The price of generic drugs is generally much lower than their brand-name counterparts due to several factors. These include competition among multiple generic manufacturers, lower research and development costs for generics (as they do not need to repeat costly clinical trials), and streamlined regulatory approval processes for generics. The exact price of a generic Pradaxa would depend on the number of companies producing it and their pricing strategies.
What is Pradaxa Used For?
Pradaxa is an anticoagulant medication used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also used to treat and prevent blood clots in the legs and lungs [2].